- Home
- RDI vs KALA Comparison
RDI vs KALA Comparison
Compare RDI & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- KALA
- Stock Information
- Founded
- RDI 1937
- KALA 2009
- Country
- RDI United States
- KALA United States
- Employees
- RDI N/A
- KALA N/A
- Industry
- RDI Movies/Entertainment
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- KALA Health Care
- Exchange
- RDI Nasdaq
- KALA Nasdaq
- Market Cap
- RDI 30.6M
- KALA 26.2M
- IPO Year
- RDI N/A
- KALA 2017
- Fundamental
- Price
- RDI $1.31
- KALA $6.90
- Analyst Decision
- RDI Hold
- KALA Strong Buy
- Analyst Count
- RDI 1
- KALA 3
- Target Price
- RDI $2.40
- KALA $14.00
- AVG Volume (30 Days)
- RDI 32.3K
- KALA 117.3K
- Earning Date
- RDI 08-13-2025
- KALA 08-05-2025
- Dividend Yield
- RDI N/A
- KALA N/A
- EPS Growth
- RDI N/A
- KALA N/A
- EPS
- RDI N/A
- KALA N/A
- Revenue
- RDI $205,644,000.00
- KALA N/A
- Revenue This Year
- RDI $7.47
- KALA N/A
- Revenue Next Year
- RDI $13.22
- KALA N/A
- P/E Ratio
- RDI N/A
- KALA N/A
- Revenue Growth
- RDI N/A
- KALA N/A
- 52 Week Low
- RDI $1.17
- KALA $2.92
- 52 Week High
- RDI $1.89
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- RDI 48.06
- KALA 77.24
- Support Level
- RDI $1.24
- KALA $4.36
- Resistance Level
- RDI $1.31
- KALA $5.75
- Average True Range (ATR)
- RDI 0.06
- KALA 0.66
- MACD
- RDI -0.00
- KALA 0.20
- Stochastic Oscillator
- RDI 50.00
- KALA 96.85
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.